 Shares of Jounce Therapeutics NASDAQ:JNCE were unaffected at 5.34 after the company reported Q1 results.Quarterly Results Earnings per share were down 105.26 year over year to 0.78, which missed the estimate of 0.57.Revenue of 0 less by 100.00 year over year, which missed the estimate of 1,670,000.Looking Ahead Jounce Therapeutics hasnt issued any earnings guidance for the time being.Jounce Therapeutics hasnt issued any revenue guidance for the time being.Details Of The Call Date: May 06, 2020View more earnings on JNCETime: 07:00 AM ETWebcast URL: Companys 52-week high was at 10.0052-week low: 2.79Price action over last quarter: Up 18.14Company Profile Jounce Therapeutics Inc is a clinical stage immunotherapy company. The company is dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients. The companys strategy is to create immunotherapies targeting a variety of the diverse cellular components of the immune system, as well as non-immune cells resident within the tumor, all of which can vary greatly among tumors within and across indications. This may provide benefit to patients with tumors across the spectrum from highly inflamed, or hot, to poorly inflamed, or cold, and especially those not well served by current therapies. Its lead product candidate, JTX-2011, is a clinical stage monoclonal antibody.See more from Benzinga Venator Materials: Q1 Earnings Insights Stocks That Hit 52-Week Lows On Tuesday Portola Pharmaceuticals: PE Ratio InsightsC 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. 